ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
22.68 USD   -1.09%
08/04ANIKA THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/03Anika Therapeutics to Seek Acquisitions
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Barrington Adjusts Price Target on Anika Therapeutics to $48 From $44, Keeps Outperform Rating

11/05/2021 | 12:31pm EDT


© MT Newswires 2021
All news about ANIKA THERAPEUTICS, INC.
08/04ANIKA THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
08/03Anika Therapeutics to Seek Acquisitions
CI
08/03TRANSCRIPT : Anika Therapeutics, Inc., Q2 2022 Earnings Call, Aug 03, 2022
CI
08/03ANIKA THERAPEUTICS : Reports Second Quarter Fiscal 2022 Financial Results - Form 8-K
PU
08/03ANIKA : Q2 Earnings Snapshot
AQ
08/03Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q2 Loss $-0.12
MT
08/03Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q2 Revenue $39.7M
MT
08/03Anika Reports Second Quarter Fiscal 2022 Financial Results
AQ
08/03Anika Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 154 M - -
Net income 2022 -11,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -28,9x
Yield 2022 -
Capitalization 331 M 331 M -
Capi. / Sales 2022 2,14x
Capi. / Sales 2023 1,93x
Nbr of Employees 297
Free-Float 98,1%
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 22,68 $
Average target price 46,00 $
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors